RxDoctor Payments Data

Stacy Thompson, APRN

Family · Rock Springs, WYNPI 1659719706

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.9% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 70.5% of it on its own, with 8 other manufacturers making up the rest.

$1,007in general payments, 2019–2025

Across 44 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$710
  • Boston Scientific$87
  • Pfizer$86
  • Lilly USA, LLC$40
  • Hikma Pharmaceuticals USA$21
  • Vertex$20
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$98698%
  • Education$212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,007 in reported general payments places this provider in the 75th percentile of 284 family providers in Wyoming.

See all family providers in Wyoming

Medicare billing

Part B allowed, 2024
$34,903
Medicare patients
90
Services billed
516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide25$33,461
OzempicSemaglutide17$27,941
VraylarCariprazine Hcl19$26,917
MounjaroTirzepatide18$26,693
Nurtec OdtRimegepant Sulfate13$23,588
LinzessLinaclotide19$17,663
FarxigaDapagliflozin Propanediol19$15,764
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$9,950
EliquisApixaban13$8,841
OxycontinOxycodone Hcl23$8,075
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl35$7,979
NexiumEsomeprazole Magnesium13$7,204
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen133$4,408
Celecoxib20$3,560
Oxycodone Hcl143$3,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$40$60,15443 claims
AbbVieVraylar, Linzess$710$44,58038 claims
PfizerNurtec Odt, Eliquis$86$32,42926 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$21$7,97935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 284 family providers in Wyoming.

Other family in Rock Springs

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →